The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 00010/0535.
Gadovist 1.0mmol/ml (Vials)
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.
If you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Gadovist® 1.0 mmol/ml solution for injection
1. What Gadovist is and what it is used for
2. What you need to know before you are given Gadovist
3. How Gadovist will be given
4. Possible side effects
5. How to store Gadovist
6. Contents of the pack and other information
Gadovist is a contrast medium for magnetic resonance imaging (MRI) used for diagnostics of the brain, spine and vessels. Gadovist can also help the doctor find out the kind (benign or malignant) of known or suspected abnormalities in the liver and kidneys.
Gadovist can also be used for MRI of abnormalities of other body regions.
It facilitates visualisation of abnormal structures or lesions and helps in the differentiation between healthy and diseased tissue.
It is for use in adults and children of all ages (including term newborn infants).
MRI is a form of medical diagnostic imaging that uses the behaviour of water molecules in normal and abnormal tissues. This is done by a complex system of magnets and radio waves. Computers record the activity and translate that into images.
Gadovist is given as an injection into your vein. This medicine is for diagnostic use only and will only be administered by healthcare professionals experienced in the field of clinical MRI practice.
Talk to your doctor before you are given Gadovist if you
Your doctor will decide whether the intended examination is possible or not.
Tell your doctor if
Your doctor may decide to take a blood test to check how well your kidneys are working before making the decision to use Gadovist, especially if you are 65 years of age or older.
As kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, Gadovist will only be used in these patients after careful consideration by the doctor.
Tell your doctor if you are taking or have recently taken or might take any other medicines.
Ask your doctor for advice before taking any medicine.
You must tell your doctor if you think you are, or might become, pregnant as Gadovist should not be used during pregnancy unless strictly necessary.
Tell your doctor if you are breast-feeding or about to start breast-feeding. Your doctor will discuss whether you should continue or interrupt breast-feeding for a period of 24 hours after you receive Gadovist.
This medicinal product contains less than 23 mg sodium per dose (based on the average amount given to a 70 kg person), i.e. essentially ‘sodium-free’.
Gadovist is injected into your vein using a small needle by a healthcare professional. Your MRI examination can start immediately.
After the injection you will be observed for at least 30 minutes.
The actual dose that is right for you will depend on your body weight and on the region being examined by MRI:
In adults a single injection of 0.1 millilitre Gadovist per kg body weight is recommended (this means for a person weighing 70 kg the dose would be 7 millilitre), however a further injection of up to 0.2 millilitre per kg body weight within 30 minutes of the first injection may be given. A total amount of 0.3 millilitre Gadovist per kg body weight may be given at maximum (this means for a person weighing 70 kg the dose would be 21 millilitres) for imaging of the central nervous system (CNS) and CE-MRA. A dose of 0.075 millilitres Gadovist per kg body weight may be given at minimum (this means for a person weighing 70 kg the dose would be 5.25 millilitres) for the CNS.
Further information regarding the administration and handling of Gadovist is given at the end of the leaflet.
The use of Gadovist is not recommended in patients with severe kidney problems and patients who have recently had, or soon expect to have, a liver transplant. However if use is required you should only receive one dose of Gadovist during a scan and you should not receive a second injection for at least 7 days.
In children of all ages (including term newborn infants) a single dose of 0.1 millilitre Gadovist per kg body weight is recommended for all examinations (see section 1).
As kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, Gadovist will only be used in these patients after careful consideration by the doctor. Neonates and infants should only receive one dose of Gadovist during a scan and should not receive a second injection for at least 7 days.
It is not necessary to adjust your dose if you are 65 years of age or older but you may have a blood test to check how well your kidneys are working.
Overdosing is unlikely. If it does happen, the doctor will treat any symptoms and may use kidney dialysis to remove Gadovist from your body.
There is no evidence to suggest that this will prevent the development of Nephrogenic Systemic Fibrosis (NSF; see section 4) and it should not be used as treatment for the condition. In some cases your heart will be checked.
If you have any further questions on the use of this medicine, ask your doctor or radiologist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most serious side effects (which have been fatal or life-threatening in some cases) are:
In addition for the following side effects life-threatening or fatal outcomes have been observed in some cases:
In rare cases:
If you notice:
tell the MRI department staff immediately. These may be the first signs that a severe reaction is happening. Your investigation may need to be stopped and you may need further treatment.
Delayed allergy-like reactions, hours to several days after you have received Gadovist, have been observed in rare cases. If this should happen to you, tell your doctor or radiologist immediately.
The most frequently observed side effects (may affect 5 or more in 1,000 people) are:
Most of the side effects are mild to moderate.
Possible side effects which have been observed in clinical trials before the approval of Gadovist are listed below by how likely they are.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Additional side effects which have been reported after the approval of Gadovist with unknown frequency (frequency cannot be estimated from the available data):
Variations in blood tests of the kidney function (e.g. increase of serum creatinine) have been observed after administration of Gadovist.
If you get any side effects talk to your doctor or radiologist. This includes any side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
or search for MHRA Yellow Card in the Google Play or Apple App Store.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions.
Chemical, physical and microbiological in-use stability has been demonstrated for 24 hours at 20-25°C. From a microbiological point of view, the product should be used immediately after opening.
This medicinal product is a clear, colorless to pale yellow solution. Do not use this medicine if you notice severe discoloration or the presence of particulate matter or if the container appears defective.
Medicines should not be disposed of via wastewater or household waste. The healthcare professional will dispose of this medicine when no longer required. These measures will help to protect the environment.
The active substance is gadobutrol.
1 ml of solution for injection contains 604.72 mg gadobutrol (equivalent to 1.0 mmol gadobutrol containing 157.25 mg gadolinium).
1 vial with 2 ml contains 1209.44 mg gadobutrol
1 vial with 7.5 ml contains 4535.4 mg gadobutrol,
1 vial with 15 ml contains 9070.8 mg gadobutrol,
1 vial with 30 ml contains 18141.6 mg gadobutrol.
1 bottle with 65 ml contains 39306.8 mg gadobutrol.
The other ingredients are calcobutrol sodium (see end of section 2), trometamol, hydrochloric acid 1N and water for injections.
Gadovist is a clear, colourless to pale yellow solution for injection.
The contents of the packs are:
Not all pack sizes may be marketed.
This leaflet was last revised in August 2022